Long-tErm Follow-uP of antithrombotIc Management Patterns In Acute CORonary Syndrome Patients in Asia
EPICOR ASIA
Long-Term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Asia
1 other identifier
observational
13,011
7 countries
108
Brief Summary
The purpose of this study is to describe the short-and long-tern (i.e. up to 2 years following the index event) AMPs in patients hospitalized for an acute coronary syndrome (i.e. STEMI or NSTE-ACS), and to document clinical outcomes, economic aspects and impact on quality of life of these AMPs in a 'real-life' setting.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2011
Typical duration for all trials
108 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 23, 2011
CompletedFirst Posted
Study publicly available on registry
May 26, 2011
CompletedStudy Start
First participant enrolled
June 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2014
CompletedJune 16, 2014
June 1, 2014
2.9 years
May 23, 2011
June 13, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
short- and long-term medication and treatment prescribed by physicians in real-life setting
up to 3 years
Secondary Outcomes (3)
clinical outcome (Cardiovascular events)
up to 3 years
cost of hospitalization
up to 3 years
quality of life (EQ-5D questionnaire)
up to 3 years
Study Arms (1)
1
Eligibility Criteria
Asian patients hospitalized for ACS within 48 hours of symptom onset and who have a final diagnosis of unstable angina (UA), STEMI or non-ST-segment elevation myocardial infarction (NSTEMI).
You may qualify if:
- Written informed consent has been provided.
- Diagnosis of STEMI, NSTEMI or UA
- Hospitalization for the first time within 48 hours of onset of symptoms.
You may not qualify if:
- UA, STEMI, NSTEMI precipitated by or as a complication of surgery, trauma, or GI bleeding or post-PCI UA, STEMI and NSTEMI occurring in patients already hospitalized for other reasons.
- Current participation in a randomised interventional clinical trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (108)
Research Site
Hefei, Anhui, China
Research Site
Wuhu, Anhui, China
Research Site
Beijing, Beijing Municipality, China
Research Site
Chongqing, Chongqing Municipality, China
Research Site
Fuzhou, Fujian, China
Research Site
Lanzhou, Gansu, China
Research Site
Foshan, Guangdong, China
Research Site
Guangzhou, Guangdong, China
Research Site
Shenzhen, Guangdong, China
Research Site
Nanning, Guangxi, China
Research Site
Yulin, Guangxi, China
Research Site
Guiyang, Guizhou, China
Research Site
Baoding, Hebei, China
Research Site
Shijiazhuang, Hebei, China
Research Site
Tangshan, Hebei, China
Research Site
Daqing, Heilongjiang, China
Research Site
Harbin, Heilongjiang, China
Research Site
Zhengzhou, Henan, China
Research Site
Shiyan, Hubei, China
Research Site
Wuhan, Hubei, China
Research Site
Changsha, Hunan, China
Research Site
Nanjing, Jiangsu, China
Research Site
Wuxi, Jiangsu, China
Research Site
Xuzhou, Jiangsu, China
Research Site
Zhenjiang, Jiangsu, China
Research Site
Changchun, Jilin, China
Research Site
Jinzhou, Liaoning, China
Research Site
Shenyang, Liaoning, China
Research Site
Yingkou, Liaoning, China
Research Site
Xining, Qinghai, China
Research Site
Xi'an, Shaanxi, China
Research Site
Jinan, Shandong, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Changzhi, Shanxi, China
Research Site
Jinzhong, Shanxi, China
Research Site
Taiyuan, Shanxi, China
Research Site
Chengdu, Sichuan, China
Research Site
Tianjin, Tianjin Municipality, China
Research Site
Shihezi, Xinjiang, China
Research Site
Urumuqi, Xinjiang, China
Research Site
Kunming, Yunnan, China
Research Site
Hangzhou, Zhejiang, China
Research Site
Hong Kong, China
Research Site
Ningxia, China
Research Site
Qingdao, China
Research Site
Hyderabad, Andhra Pradesh, India
Research Site
Guwahati, Assam, India
Research Site
Ahmedabad, Gujarat, India
Research Site
Surat, Gujarat, India
Research Site
Vadodara, Gujarat, India
Research Site
Gurgaon, Haryana, India
Research Site
Bangalore, Karnataka, India
Research Site
Manipal, Karnataka, India
Research Site
Kochi, Kerala, India
Research Site
Trivandrum, Kerala, India
Research Site
Bhopal, Madhya Pradesh, India
Research Site
Bilāspur, Madhya Pradesh, India
Research Site
Aurangabad, Maharashtra, India
Research Site
Mumbai, Maharashtra, India
Research Site
Nagpur, Maharashtra, India
Research Site
Pune, Maharashtra, India
Research Site
Delhi, National Capital Territory of Delhi, India
Research Site
Ludhiana, Punjab, India
Research Site
Mohali, Punjab, India
Research Site
Ajmer, Rajasthan, India
Research Site
Jaipur, Rajasthan, India
Research Site
Chennai, Tamil Nadu, India
Research Site
Coimbatore, Tamil Nadu, India
Research Site
Madurai, Tamil Nadu, India
Research Site
Lucknow, Uttar Pradesh, India
Research Site
Kolkata, West Bengal, India
Research Site
Sarawak, Kuching, Malaysia
Research Site
George Town, Malaysia
Research Site
Singapore, Singapore
Research Site
Busan, Busan, South Korea
Research Site
Chuncheon, Chuncheon, South Korea
Research Site
Cheonan, Chungcheongnam-do, South Korea
Research Site
Deagu, Deagu, South Korea
Research Site
Gwangju, Gwangju, South Korea
Research Site
Bucheon-si, Gyeonggi-do, South Korea
Research Site
Goyang-si, Gyeonggi-do, South Korea
Research Site
Suwon, Gyeonggi-do, South Korea
Research Site
Yangsan, Gyeongsangnam-do, South Korea
Research Site
Jeju City, Jeju-do, South Korea
Research Site
Iksan, Jeollabuk-do, South Korea
Research Site
Seoul, Seoul, South Korea
Research Site
Bangkoknoi, Bangkok, Thailand
Research Site
Huaykwang, Bangkok, Thailand
Research Site
PathumWan, Bangkok, Thailand
Research Site
Payathai, Bangkok, Thailand
Research Site
Rachathevi, Bangkok, Thailand
Research Site
Saimai, Bangkok, Thailand
Research Site
Muang, Changwat Chanthaburi, Thailand
Research Site
Muang, Changwat Chon Buri, Thailand
Research Site
Muang, Changwat Lampang, Thailand
Research Site
Muang, Changwat Nan, Thailand
Research Site
Klongluang, Changwat Pathum Thani, Thailand
Research Site
Muang, Changwat Phitsanulok, Thailand
Research Site
Muang, Changwat Songkhla, Thailand
Research Site
Muang, Changwat Suphan Buri, Thailand
Research Site
Muang, Changwat Surat Thani, Thailand
Research Site
Muang, Chiangmai, Thailand
Research Site
Muang, Chiangrai, Thailand
Research Site
Muang, Khonkaen, Thailand
Research Site
Muang, Nakornratchaseema, Thailand
Research Site
Muang, Udonthani, Thailand
Research Site
Ho Chi Minh City, Ho Chi Minh City, Vietnam
Research Site
Huế, Hue, Vietnam
Related Publications (4)
Huo Y, Van de Werf F, Han Y, Rossello X, Pocock SJ, Chin CT, Lee SW, Li Y, Jiang J, Vega AM, Medina J, Bueno H. Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia. Am J Cardiovasc Drugs. 2021 Jul;21(4):471-482. doi: 10.1007/s40256-020-00447-5. Epub 2021 Feb 4.
PMID: 33537947DERIVEDGuan S, Xu X, Li Y, Li J, Guan M, Wang X, Jing Q, Huo Y, Han Y. Impact of Diabetes Mellitus on Antithrombotic Management Patterns and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndrome: Insights From the EPICOR Asia Study. J Am Heart Assoc. 2020 Nov 17;9(22):e013476. doi: 10.1161/JAHA.119.013476. Epub 2020 Nov 7.
PMID: 33164633DERIVEDZhang S, Wang W, Sawhney JPS, Krittayaphong R, Kim HS, Nhan VT, Lee SW, Ong TK, Chin CT, Pocock SJ, Huo Y, Qian J, Ge J. Antithrombotic management and long-term outcomes following percutaneous coronary intervention for acute coronary syndrome in Asia. Int J Cardiol. 2020 Jul 1;310:16-22. doi: 10.1016/j.ijcard.2020.01.008. Epub 2020 Mar 17.
PMID: 32192746DERIVEDJan S, Lee SW, Sawhney JPS, Ong TK, Chin CT, Kim HS, Krittayaphong R, Nhan VT, Pocock SJ, Vega AM, Hayashi N, Huo Y. Predictors of high-cost hospitalization in the treatment of acute coronary syndrome in Asia: findings from EPICOR Asia. BMC Cardiovasc Disord. 2018 Jul 4;18(1):139. doi: 10.1186/s12872-018-0859-4.
PMID: 29973147DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Guy Yeoman
AstraZeneca
- STUDY CHAIR
Prof. Huo Yong
Peking University 1st Hospital
- STUDY CHAIR
Jayanti Visvanathan
AstraZeneca
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 23, 2011
First Posted
May 26, 2011
Study Start
June 1, 2011
Primary Completion
May 1, 2014
Study Completion
May 1, 2014
Last Updated
June 16, 2014
Record last verified: 2014-06